zabmedvestnikЗабайкальский медицинский вестникTransbaikalian Medical Bulletin1998-6173Читинская государственная медицинская академия10.52485/19986173_2025_2_95zabmedvestnik-385Research ArticleНАУЧНЫЕ ОБЗОРЫSCIENTIFIC REVIEWSРаспространенность и генетические предикторы нарушений липидного обменаPrevalence and genetic predictors of lipid metabolism disordershttps://orcid.org/0000-0002-2741-3783ЗайцевД. Н.ZaitsevD. N.

Дмитрий Николаевич Зайцев, д. м. н., профессор, заведующий кафедрой

базовая кафедра

664003; ул. Красного Восстания, д. 1; Иркутск

AuthorID: 324250

Doctor of Medical Sciences, Professor, Head of the Department

Basic Department

664003; 1 Krasny Vosstaniya St.; Irkutsk

AuthorID: 324250

zaycevdn@mail.ruhttps://orcid.org/0000-0003-2515-9619СлободскаяИ. В.SlobodskayaI. V.

Ирина Владимировна Слободская, аспирант, врач-кардиолог

кафедра факультетской терапии

672000; ул. Горького, 39а; Чита

Postgraduate Student, cardiologist

Department of Faculty Therapy

672000; 39a Gorky St.; Chita

AuthorID: 1177233

iv_s93@mail.ruhttps://orcid.org/0000-0002-7968-6417ВасиленкоП. В.VasilenkoP. V.

Павел Владимирович Василенко, к. м. н., доцент

кафедра факультетской терапии

672000; ул. Горького, 39а; Чита

AuthorID: 1013777

Сandidate of Medical Sciences, Associate Professor

Department of Faculty Therapy

672000; 39a Gorky St.; Chita

AuthorID: 1013777

pavelvasilenkochita@mail.ruФГБОУ ВО "Иркутский государственный медицинский университет" Министерства здравоохранения РФРоссияIrkutsk State Medical UniversityRussian FederationФГБОУ ВО «Читинская государственная медицинская академия» Министерства здравоохранения РФРоссияChita State Medical AcademyRussian Federation2025040720250295105Copyright © Зайцев Д.Н., Слободская И.В., Василенко П.В., 20252025Зайцев Д.Н., Слободская И.В., Василенко П.В.Zaitsev D.N., Slobodskaya I.V., Vasilenko P.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.zabmedvestnik.ru/jour/article/view/385

   Представлен обзор литературы о распространенности и генетических причинах нарушений липидного обмена, проанализированы результаты основных исследований и регистров, посвященных изучению эпидемиологических особенностей дислипидемий.

   A review of the literature on the prevalence and genetic causes of lipid metabolism disorders is presented, the results of major studies and registries devoted to the study of the epidemiological features of dyslipidemia are analyzed.

нарушения липидного обменагиперхолестеринемияполиморфизм геновlipid metabolism disordershypercholesterolemiagene polymorphismИсследование не имело финансовой поддержкиThe study had no financial supportReferencesКожокарь К.Г., Урванцева И.А. Совершенствование медицинской помощи пациентам с нарушениями липидного обмена (на примере работы липидного центра «Окружного кардиологического диспансера «Центр диагностики и сердечно-сосудистой хирургии», г. Сургут). Российский кардиологический журнал. 2017. 5. 97–103.Kozhokar K.G., Urvantseva I.A. Improving medical care for patients with lipid metabolism disorders (based on the work of the lipid center of the District Cardiology Dispensary "Center for Diagnostics and Cardiovascular Surgery", Surgut). Russian Journal of Cardiology. 2017. 5. 97-103.Здравоохранение в России. 2023 : Статистический сборник. Росстат. Москва. 2023. 179.Healthcare in Russia. 2023: Statistical Digest. Rosstat. Moscow. 2023. 179.Кухарчук В.В., Ежов М.В., Сергиенко И.В. и соавт. Клинические рекомендации Евразийской ассоциации кардиологов (ЕАК). Национального общества по изучению атеросклероза (НОА) по диагностике и коррекции нарушений липидного обмена с целью профилактики и лечения атеросклероза (2020). Евразийский кардиологический журнал. 2020. 2. 6–29.Kukharchuk V.V., Yezhov M.V., Sergienko I.V. et al. Clinical guidelines of the Eurasian Association of Cardiologists (EAC)/National Society for the Study of Atherosclerosis (NSSA) for the diagnosis and correction of lipid metabolism disorders for the prevention and treatment of atherosclerosis (2020). Eurasian Journal of Cardiology. 2020. 2. 6-29.Садыкова Д.И., Зиатдинов А.И., Сенек А.И. и соавт. Опыт организации медицинской помощи детям с нарушениями липидного обмена на примере работы Центра липидологии Детской Республиканской клинической больницы в Республике Татарстан. Атеросклероз и дислипидемии. 2021. 1(42). 52–58.Sadykova D.I., Ziatdinov A.I., Senek A.I. et al. Experience in organizing medical care for children with lipid metabolism disorders using the example of the work of the Lipidology Center of the Children's Republican Clinical Hospital in the Republic of Tatarstan. Atherosclerosis and dyslipidemia. 2021. 1(42). 52–58.Метельская В.А., Шальнова С.А., Деев А.Д. и соавт. Анализ распространенности показателей, характеризующих атерогенность спектра липопротеинов, у жителей Российской Федерации (по данным исследования ЭССЕ-РФ). Профилактическая медицина. 2016. 19 (1). 15–23.Metelskaya V.A., Shalnova S.A., Deev A.D. et al. Analysis of the prevalence of indicators characterizing the atherogenicity of the lipoprotein spectrum in residents of the Russian Federation (according to the ESSE-RF study). Preventive Medicine. 2016. 19(1). 15-23.Ежов М.В., Кухарчук В.В., Сергиенко И.В. и соавт. Нарушения липидного обмена. Клинические рекомендации 2023. Российский кардиологический журнал. 2023. 5.Ezhov M.V., Kukharchuk V.V., Sergienko I.V. et al. Lipid metabolism disorders. Clinical guidelines 2023. Russian journal of cardiology. 2023. 5.Chapman M.J., Ginsberg H.N., Amarenco P. et al. Triglyceride-rich lipoproteins and highdensity lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. European Heart Journal. 2011. 32. 1345–1361.Chapman M.J., Ginsberg H.N., Amarenco P. et al. Triglyceride-rich lipoproteins and highdensity lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. European Heart Journal. 2011. 32. 1345-1361.Кардиоваскулярная профилактика 2017: российские национальные рекомендации. Российский кардиологический журнал. 2018. 6. 7–122. DOI: 10.15829/1560-4071-2018-6-7-122.Cardiovascular prevention 2017 : Russian national recommendations. Russian journal of cardiology. 2018. 6. 7-122. DOI: 10.15829/1560-4071-2018-6-7-122.Yusuf S., Hawken S., Ounpuu S. et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. The Lancet. 2004. 364. P. 937-952. DOI: 10.1016/S0140-6736(04)17018-9.Yusuf S., Hawken S., Ounpuu S. et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. The Lancet. 2004. 364. P. 937-952. DOI: 10.1016/S0140-6736(04)17018-9.Драпкина О.М., Имаева А.Э., Куценко В.А. и соавт. Дислипидемии в Российской Федерации: популяционные данные, ассоциации с факторами риска. Кардиоваскулярная терапия и профилактика. 2023. 22(8S):3791. DOI: 10.15829/1728-8800-2023-3791.Drapkina O.M., Imaeva A.E., Kutsenko V.A. et al. Dyslipidemias in the Russian Federation: population data, associations with risk factors. Cardiovascular Therapy and Prevention.2023. 22(8S):3791. DOI: 10.15829/1728-8800-2023-3791.Kotseva K, Wood D., De Wood G. et al. EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries. Eur J CardiovascPrev Rehabil. 2010. 17 (5). 530–540. DOI:10.1097/HJR.0b013e3283383f30.Kotseva K, Wood D., De Wood G. et al. EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries. Eur J CardiovascPrev Rehabil. 2010. 17 (5). 530-540. DOI: 10.1097/HJR.0b013e3283383f30.Ежов М.В., Близнюк С.А., Алексеева И.А. и соавт. Распространенность гиперхолестеринемии и применения статинов в амбулаторной практике в Российской Федерации. Исследование АЙСБЕРГ. диАгностирование пациентов с гиперхолестеринемиеЙ в уСловиях амБулаторной практики на раннЕм этапе с целью улучшения сеРдечно-сосудистого проГноза. Атеросклероз и дислипидемии. 2017. 4. 5-18.Ezhov M.V., Bliznyuk S.A., Alekseeva I.A. et al. Prevalence of hypercholesterolemia and statin use in outpatient practice in the Russian Federation. The ICEBERG study - early diagnosis of patients with hypercholesterolemia in outpatient practice to improve cardiovascular prognosis. Atherosclerosis and dyslipidemia. 2017. 4. 5-18.Ахмеджанов Н.М., Небиеридзе Д.В., Сафарян А.С. и соавт. Анализ распространенности ГХС в условиях амбулаторной практики (по данным исследования АРГО): часть 1. Рациональная фармакотерапия в кардиологии. 2015. 11 (3).Akhmedzhanov N.M., Nebieridze D.V., Safaryan A.S. et al. Analysis of the prevalence of hypercholesterolemia in outpatient practice (according to the ARGO study): part 1. Rational pharmacotherapy in cardiology. 2015. 11(3).Бойцов С.А., Лукьянов М.М., Якушин С.С. и соавт. Амбулаторно-поликлинический регистр РЕКВАЗА: данные проспективного наблюдения, оценка риска и исходы у больных с кардиоваскулярными заболеваниями. Кардиоваскулярная терапия и профилактика. 2015. 14 (1). 53–62.Boytsov S.A., Lukyanov M.M., Yakushin S.S. et al. Outpatient and polyclinic registry REKVAZA: data of prospective observation, risk assessment and outcomes in patients with cardiovascular diseases. Cardiovascular Therapy and Prevention. 2015. 14(1). 53-62.Muntner P., Lee F., Astor B.C. Association of high-density lipoprotein cholesterol with coronary heart disease risk across categories of low-density lipoprotein cholesterol: the atherosclerosis risk in communities study. American Journal of the Medical Sciences. 2011. 341(3). 173-80. DOI: 10.1097/MAJ.0b013e3181f97e4a.Muntner P., Lee F., Astor B.C. Association of high-density lipoprotein cholesterol with coronary heart disease risk across categories of low-density lipoprotein cholesterol: the atherosclerosis risk in communities study. American Journal of the Medical Sciences. 2011. 341(3). 173-80. DOI: 10.1097/MAJ.0b013e3181f97e4a.Aguiar C., Alegria E., Bonadonna R.C.et al. A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy. Atherosclerosis Supplements. 2015. 19. 1–12. DOI: 10.1016/S1567-5688(15)30001-5.Aguiar C., Alegria E., Bonadonna R.C.et al. A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy. Atherosclerosis Supplements. 2015. 19. 1-12. DOI: 10.1016/S1567-5688(15)30001-5.Castelli W.P. Epidemiology of triglycerides: a view from Framingham. American Journal of Cardiology. 1992. 70 (19). 3–9. DOI: 10.1016/0002-9149(92)91083-G.Castelli W.P. Epidemiology of triglycerides: a view from Framingham. American Journal of Cardiology. 1992. 70(19). 3-9. DOI: 10.1016/0002-9149(92)91083-G.Barter P., Gotto A.M., LaRosa J.C. et al. HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular Events. New England Journal of Medicine. 2007. 357. 1301–1310. DOI: 10.1056/NEJMoa064278.Barter P., Gotto A.M., LaRosa J.C. et al. HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular Events. New England Journal of Medicine. 2007. 357. 1301-1310. DOI: 10.1056/NEJMoa064278.Carey V.J., Bishop L., Laranjo N. et al. Contribution of high plasma triglycerides and low high-density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low-density lipoprotein cholesterol control. American Journal of Cardiology. 2010. 106 (6). 757–763. DOI: 10.1016/j.amjcard.2010.05.002.Carey V.J., Bishop L., Laranjo N. et al. Contribution of high plasma triglycerides and low high-density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low-density lipoprotein cholesterol control. American Journal of Cardiology. 2010. 106(6). 757-763. DOI: 10.1016/j.amjcard.2010.05.002.Карпов Ю.А. Распространенность гипертриглицеридемии: новые всероссийские данные. Исследование PROMETHEUS. Кардиология. 2016. 5 (7). 63–71.Karpov Yu.A. Prevalence of hypertriglyceridemia: new all-Russian data. PROMETHEUS study. Cardiology. 2016. 5(7). 63-71.Мустафина С.В., Никитин Ю.П., Симонова Г.И., Щербакова Л.В. Распространенность дислипидемий при сахарном диабете в возрасте 45–69 лет в г. Новосибирске. Атеросклероз. 2014. 10 (4). 26–31.Mustafina S.V., Nikitin Yu.P., Simonova G.I., Shcherbakova L.V. Prevalence of dyslipidemia in diabetes mellitus at the age of 45–69 years in Novosibirsk. Atherosclerosis. 2014. 10(4). 26-31.Hopkins P.N., Toth P.P, Ballantyne C.M., Rader D.J. Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. Journal of Clinical Lipidology. 2011. 5 (3). 9–17. DOI: 10.1016/j.jacl.2011.03.45.Hopkins P.N., Toth P.P, Ballantyne C.M., et al. Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. Journal of Clinical Lipidology. 2011. 5(3). 9-17. DOI: 10.1016/j.jacl.2011.03.45.Sharifi M., Futema M., Nair D., Humphries S.E. Genetic Architecture of Familial Hypercholesterolaemia. Current Cardiology Reports. 2017. 19 (5). 24.Sharifi M., Futema M., Nair D., et al. Genetic Architecture of Familial Hypercholesterolaemia. Current Cardiology Reports. 2017. 19 (5). 24.Humphries S.E., Norbury G., Leigh S. et al. What is the clinical utility of DNA testing in patients with familial hypercholesterolaemia? Current Cardiology Reports. 2008. 19. 362–368.Humphries S.E., Norbury G., Leigh S. et al. What is the clinical utility of DNA testing in patients with familial hypercholesterolaemia? Current Cardiology Reports. 2008. 19. 362-368.Akioyamen L.E., Genest J., Shan S.D. et al. Estimating the prevalence of heterozygous familial hypercholesterolaemia : a systematic review and meta-analysis. BMJ Open. 2017. 7 (9). DOI: 10.1136/bmjopen-2017-016461.Akioyamen L.E., Genest J., Shan S.D. et al. Estimating the prevalence of heterozygous familial hypercholesterolaemia : a systematic review and meta-analysis. BMJ Open. 2017. 7(9). DOI: 10.1136/bmjopen-2017-016461.Ежов М.В., Бажан С.С., Ершова А.И. и соавт. Клинические рекомендации по семейной гиперхолестеринемии. Атеросклероз. 2019. 15 (1). 58–98.Ezhov M.V., Bazhan S.S., Ershova A.I. et al. Clinical guidelines for familial hypercholesterolemia. Atherosclerosis. 2019. 15(1). 58-98.Бойцов С.А., Драпкина О.М., Шляхто Е.В. и соавт. Исследование ЭССЕ-РФ (Эпидемиология сердечно-сосудистых заболеваний и их факторов риска в регионах Российской Федерации). Десять лет спустя. Кардиоваскулярная терапия и профилактика. 2021. 20 (5). 3007.Boytsov S.A., Drapkina O.M., Shlyakhto E.V. et al. Study ESSE-RF (Epidemiology of cardiovascular diseases and their risk factors in the regions of the Russian Federation). Ten years later. Cardiovascular therapy and prevention. 2021. 20(5). 3007.Meshkov A.N., Ershova A.I., Kiseleva A.V. et al. The Prevalence of Heterozygous Familial Hypercholesterolemia in Selected Regions of the RussianFederation: The FH-ESSE-RF Study. Journal Personalized Medicine. 2021. 11 (6). 464. DOI: 10.3390/jpm11060464.Meshkov A.N., Ershova A.I., Kiseleva A.V. et al. The Prevalence of Heterozygous Familial Hypercholesterolemia in Selected Regions of the RussianFederation: The FH-ESSE-RF Study. Journal Personalized Medicine. 2021. 11(6). 464. DOI: 10.3390/jpm11060464.Ежов М.В., Близнюк С.А., Тмоян Н.А. и соавт. Регистр пациентов с семейной гиперхолестеринемией и пациентов очень высокого сердечно-сосудистого риска с недостаточной эффективностью проводимой гиполипидемической терапии (РЕНЕССАНС). Российский кардиологический журнал. 2019. 5.Ezhov M.V., Bliznyuk S.A., Tmoyan N.A. et al. Registry of patients with familial hypercholesterolemia and patients with very high cardiovascular risk with insufficient effectiveness of lipid-lowering therapy (RENAISSANCE). Russian Journal of Cardiology. 2019. 5.Сафарова М.С., Сергиенко И.В., Ежов М.В. и соавт. Российская научно-исследовательская программа по своевременной диагностике и лечению больных семейной гиперхолестеринемией: обоснование и дизайн российского регистра семейной гиперхолестеринемии (РоСГХС). Атеросклероз и дислипидемии. 2014. 3.Safarova M.S., Sergienko I.V., Ezhov M.V. et al. Russian research program for timely diagnosis and treatment of patients with familial hypercholesterolemia: rationale and design of the Russian registry of familial hypercholesterolemia (RoFH). Atherosclerosis and dyslipidemia. 2014. 3.Ежов М.В., Сергиенко И.В., Дупляков Д.В. и соавт. Результаты Российской научно-исследовательской программы по диагностике и лечению больных семейной гиперхолестеринемией. Высокая распространенность, низкая информированность, плохая приверженность. Атеросклероз и дислипидемии. 017. 2.Yezhov M.V., Sergienko I.V., Duplyakov D.V. et al. Results of the Russian research program for diagnosis and treatment of patients with familial hypercholesterolemia. High prevalence, low awareness, poor adherence. Atherosclerosis and dyslipidemia. 2017. 2.Чубыкина У.В., Ежов М.В., Рожкова Т.А. и соавт. Пятилетний период наблюдения за пациентами с гомо- и гетерозиготной семейной гиперхолестеринемией в регистре РЕНЕССАНС. Атеросклероз и Дислипидемии. 2023. 1 (50). 5–18.Chubykina U.V., Ezhov M.V., Rozhkova T.A. et al. Five-year follow-up of patients with homo- and heterozygous familial hypercholesterolemia in the RENAISSANCE registry. Atherosclerosis and Dyslipidemia. 2023. 1(50). 5–18Farup P.G., Rootwelt H., Hestad K. APOE a genetic marker of comorbidity in subjects with morbid obesity. BMC Medical Genetics. 2020. 21 (1). 146. DOI: 10.1186/s12881-020-01082-2Farup P.G., Rootwelt H., Hestad K. APOE — a genetic marker of comorbidity in subjects with morbid obesity. BMC Medical Genetics. 2020. 21(1). 146. DOI: 10.1186/s12881-020-01082-2Zhang Z., Ou J., Cai P. et al. Association between the PON1 Q192R polymorphism and coronary heart disease in Chinese: a meta-analysis. Medicine (Baltimore). 2018. 97 (26). DOI: 10.1097.Zhang Z., Ou J., Cai P. et al. Association between the PON1 Q192R polymorphism and coronary heart disease in Chinese: a meta-analysis. Medicine (Baltimore). 2018. 97(26). DOI: 10.1097.Norata G.D., Tsimikas S., Pirillo A., et al. Apolipoprotein C-III: From pathophysiology to pharmacology. Trends in Pharmacological Sciences. 2015. 36. 675-687. DOI: 10.1016/j.tips.2015.07.001.Norata G.D., Tsimikas S., Pirillo A., et al. Apolipoprotein C-III: From pathophysiology to pharmacology. Trends in Pharmacological Sciences. 2015. 36. 675-687. DOI: 10.1016/j.tips.2015.07.001.Agirbasli M., Sumerkan M.C., Eren F., et al. The S447X variant of lipoprotein lipase gene is inversely associated with severity of coronary artery disease. Heart Vessels. 2011. 26 (4). 457–63.Agirbasli M., Sumerkan M.C., Eren F., et al. The S447X variant of lipoprotein lipase gene is inversely associated with severity of coronary artery disease. Heart Vessels. 2011. 26(4). 457-63.DOI: 10.1007/s00380-010-0077-1.DOI: 10.1007/s00380-010-0077-1.He K., Zhu Z., Chen Y. Lipoprotein Lipase Gene Polymorphisms Are Associated with Myocardial Infarction Risk: A Meta-Analysis. Genetic Testing and Molecular Biomarkers. 2021. 25 (6). 434–444. DOI: 10.1089/gtmb.2021.0042.He K., Zhu Z., Chen Y. Lipoprotein Lipase Gene Polymorphisms Are Associated with Myocardial Infarction Risk: A Meta-Analysis. Genetic Testing and Molecular Biomarkers. 2021. 25(6). 434-444. DOI: 10.1089/gtmb.2021.0042.Gigek Cde O., Chen E.S., Cendoroglo M.S. et al. Association of lipase lipoprotein polymorphisms with myocardial infarction and lipid levels. Clinical Chemistry and Laboratory Medicine. 2007. 45 (5). 599–604. DOI: 10.1515/CCLM.2007.Gigek Cde O., Chen E.S., Cendoroglo M.S. et al. Association of lipase lipoprotein polymorphisms with myocardial infarction and lipid levels. Clinical Chemistry and Laboratory Medicine. 2007. 45(5). 599-604. DOI: 10.1515/CCLM.2007.Ahmadi Z., Senemar S., Radmanesh S.J. The association of lipoprotein lipase genes, HindIII and S447X polymorphisms with coronary artery disease in shiraz city. Cardiovascular and Thoracic Research. 2015. 7 (2). 63–67Ahmadi Z., Senemar S., Radmanesh S.J. The association of lipoprotein lipase genes, HindIII and S447X polymorphisms with coronary artery disease in shiraz city. Cardiovascular and Thoracic Research. 2015. 7(2). 63-67Ayyappa K.A., Shatwan I., Bodhini D. et al. High fat diet modifies the association of lipoprotein lipase gene polymorphism with high density lipoprotein cholesterol in an Asian Indian population. Nutrition & Metabolism. 2017.14 (8).Ayyappa K.A., Shatwan I., Bodhini D. et al. High fat diet modifies the association of lipoprotein lipase gene polymorphism with high density lipoprotein cholesterol in an Asian Indian population. Nutrition & Metabolism. 2017.14(8).Anderson J.L., King G.J., Bair T.L. Association of lipoprotein lipase gene polymorphisms with coronary artery disease. Journal of the American College of Cardiology. 1999. 15 (33/4). 1013–1020.Anderson J.L., King G.J., Bair T.L. Association of lipoprotein lipase gene polymorphisms with coronary artery disease. Journal of the American College of Cardiology. 1999. 15(33/4). 1013-1020.Bahrami M, B. Hamzeh M., Mohammad M.J. et al. Lipoprotein lipase gene variants: Association with acute myocardial infarction and lipid profiles. Egyptian Journal of Medical Human Genetics. 2015. 6 (4). 327–332Bahrami M, B. Hamzeh M., Mohammad M.J. et al. Lipoprotein lipase gene variants: Association with acute myocardial infarction and lipid profiles. Egyptian Journal of Medical Human Genetics. 2015. 6(4). 327-332Duman B.S., Turkoğlu C., Akpinar B. et al. Lipoprotein lipase gene polymorphism and lipid profile in coronary artery disease. Archives of Pathology & Laboratory Medicine. 2004. 128 (8). 869–874.Duman B.S., Turkoğlu C., Akpinar B. et al. Lipoprotein lipase gene polymorphism and lipid profile in coronary artery disease. Archives of Pathology & Laboratory Medicine. 2004. 128(8). 869-874.Kastelein J.J., Ordovas J.M., Wittekoek M.E. et al. Two common mutations (D9N, N291S) in lipoprotein lipase: a cumulative analysis of their influence on plasma lipids and lipoproteins in men and women. Clinical Genetics. 1999. 56 (4). 297–305. DOI: 10.1034/j.1399-0004.1999.560407.Kastelein J.J., Ordovas J.M., Wittekoek M.E. et al. Two common mutations (D9N, N291S) in lipoprotein lipase: a cumulative analysis of their influence on plasma lipids and lipoproteins in men and women. Clinical Genetics. 1999. 56(4). 297-305. DOI: 10.1034/j.1399-0004.1999.560407.Albert M.A., Danielson E., Rifai N., et al. PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. Journal of the American Medical Association. 2001. 286 (1). 64–70. DOI: 10.1001/jama.286.1.64.Albert M.A., Danielson E., Rifai N., et al. PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. Journal of the American Medical Association. 2001. 286(1). 64-70. DOI: 10.1001/jama.286.1.64.Krauss R.M., Mangravite L.M., Smith J.D. et al. Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment. Circulation. – 2008. 117. 1537–1544. DOI: 10.1161/CIRCULATIONAHA.107.708388.Krauss R.M., Mangravite L.M., Smith J.D. et al. Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment. Circulation. – 2008. 117. 1537-1544. DOI: 10.1161/CIRCULATIONAHA.107.708388.Donnelly L.A., Doney A.S., Dannfald J. et al. A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study. Pharmacogenet Genomics. 2008. 18. 1021–1026. DOI: 10.1097/FPC.0b013e3283106071.Donnelly L.A., Doney A.S., Dannfald J. et al. A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study. Pharmacogenet Genomics. 2008. 18. 1021-1026. DOI: 10.1097/FPC.0b013e3283106071.Polisecki E., Muallem H., Maeda N. et al. Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) Investigatorset al. Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER. Atherosclerosis. 2008. 200. 109–114. DOI: 10.1016/j.atherosclerosis.2007.12.004.Polisecki E., Muallem H., Maeda N. et al. Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) Investigatorset al. Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER. Atherosclerosis. 2008. 200. 109-114. DOI: 10.1016/j.atherosclerosis.2007.12.004.Цыганкова Д.П., Мулерова Т.А., Огарков М.Ю и соавт. Показатели липидного обмена у жителей Горной Шории: этнические особенности и влияние условий проживания. Атеросклероз и дислипидемии. 2017. 1.Tsygankova D.P., Mulerova T.A., Ogarkov M.Yu. et al. Lipid metabolism indices in residents of Gornaya Shoria: ethnic characteristics and influence of living conditions. Atherosclerosis and dyslipidemia. 2017. 1.Аверьянова И.В., Максимов А.Л. Состояние липидного и углеводного обмена у студентов-аборигенов и европеоидов с различными сроками проживания на территории Магаданской области. Экология человека. 2015. 9. 44–49.Averianova I.V., Maksimov A.L. State of lipid and carbohydrate metabolism in aboriginal and Caucasian students with different periods of residence in the Magadan Region. Human ecology. 2015. 9. 44-49.Рябова Т.И, Попова Т.В., Сиротин Б.З. Особенности липидного спектра сыворотки крови у коренного и пришлого населения Приамурья. Клиническая лабораторная диагностика. Москва. 2012. 2. 25–27.Ryabova T.I., Popova T.V., Sirotin B.Z. Features of the lipid spectrum of blood serum in the indigenous and immigrant population of the Amur region. Clinical laboratory diagnostics. 2012. 2. 25-27.

The authors declare that there are no conflicts of interest present.